铂类药物与肌肉不良反应关联分析

We collected data on adverse reaction reports involving platinum-based drug therapy and muscle-related adverse reactions submitted to the Food and Drug Administration Adverse Event Reporting System (FAERS) from 2013 to 2023 and to the World Health Organization's global pharmacovigilance database (VigiBase) from 1968 to 2023. We used the Reporting Odds Ratio (ROR) method for disproportionality analysis to evaluate the association between platinum-based drugs and muscle adverse reactions. This analysis was supplemented with local patient data, cellular and animal experiments. Finally, we integrated the pan-cancer transcriptome data from The Cancer Genome Atlas (TCGA) program and the transcriptome data of mouse muscle tissue treated with platinum-based drugs to investigate the relevant biological mechanisms.